IMMUNOLOGY2026™ Conference Recordings For Attendees-GNTI-932: A Targeted, Scalable, and Hypoimmune Allogeneic Engineered Treg therapy for the treatment of Inflammatory Bowel Disease.

GNTI-932: A Targeted, Scalable, and Hypoimmune Allogeneic Engineered Treg therapy for the treatment of Inflammatory Bowel Disease.

Back to course

Video Transcription

Video Summary

Martina Sassone Corsi presented GentlyBio’s engineered T-regulatory cell therapy, GentlyN3.2, for inflammatory bowel disease. She explained that current immunosuppressants and biologics are often broad, costly, and ineffective for some patients, while T-reg cells offer a more specific way to restore immune balance. GentlyN3.2 is designed around four pillars: stability, growth support, immune evasion, and gut targeting. The platform uses engineering to maintain FOXP3 expression, provide tunable IL-2 signaling, evade T- and NK-cell rejection, and direct cells to the colon and ileum. She described preclinical data showing that the cells remain stable, do not become pro-inflammatory, suppress effector T-cell proliferation, and localize to inflamed gut tissue. In mouse colitis models, the therapy reduced pathology and inflammatory markers. Overall, the talk highlighted GentlyN3.2 as a potentially scalable, long-lasting treatment for Crohn’s disease and ulcerative colitis.

Meta Tag

Date April 16, 2026 1:00 PM - 1:15 PM

Room 253

Session Therapeutic Modulation of T Cells for Autoimmune Diseases

Speaker Martina Sassone-Corsi

Track Therapeutic Approaches to Autoimmunity (THER)

Year 2026

Keywords

GentlyBio

GentlyN3.2

T-regulatory cell therapy

inflammatory bowel disease

Crohn’s disease

April 16, 2026 1:00 PM - 1:15 PM

253

Therapeutic Modulation of T Cells for Autoimmune Diseases

Martina Sassone-Corsi

Therapeutic Approaches to Autoimmunity (THER)

2026